Neuroendocrine Tumor Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Neuroendocrine Tumor Treatment Market is Segmented by Product (Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy and Others), Indication, End User and Geography

Market Snapshot

Neuroendocrine Tumor Treatment Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10 %
Neuroendocrine Tumor Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The neuroendocrine tumor treatment market will show rapid growth due to the increasing prevalence of neuroendocrine carcinoma, technological advancements and rising number of government initiatives.

As per the American Society of Clinical Oncology (ASCO) data, the prevalence of neuroendocrine tumors is increasing across the globe, though being a rare disease as it is estimated that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the United States. Therefore the increasing prevalence of neuroendocrine tumors helps in the adoption rate of the drugs for the treatment this rare disease.

The cost of development of these orphan drugs is significantly higher as compared with the other drugs which is expected to hamper the growth of the neuroendocrine tumors market during the forecast period. There is also significant increase in government initiatives and funding by various international organizations that is anticipated to boost the overall market in the near future.

Scope of the Report

As per the scope of the report, the neuroendocrine tumor is the rare tumor that arises from specialized body cells, called neuroendocrine cells, is known as neuroendocrine tumor. The neuroendocrine tumor arises from cells that produce hormones thus, it produces and releases hormones into the blood in response to signals received from the nervous system. It can occur anywhere in the body, but most commonly occurs in the pancreas, digestive tract, lungs, rectum, and appendix. Neuroendocrine tumor can be either benign (non-cancerous) or malignant (cancerous).

By Products
Somatostatin Analogs (SSAs)
Targeted Therapy
Chemotherapy
Others
By Indication
Lungs
Pancreas
Gastrointestinal
Others
By End User
Hospitals
Clinics
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Somatostatin Analogs is Expected to Dominate the Neuroendocrine Tumor Treatment Market During the Forecast Period

The Somatostatin Analogs (SSAs) are found to be the widely drugs used for the treatment of neuroendocrine carcinoma as they control cancer growth, symptoms, and target biomarkers. They are accounted for the largest revenue share owing to safe treatment procedure offered by SSAs.

SSAs are found to be generally used to treat patients who are resistant to radiation therapy and surgery. Many SSAs are thus currently under clinical trial phase and waiting for approval, hence the market is expected to witness high growth over the forecast period.

Neuroendocrine Tumor Treatment Market Share

North America is Anticipated to Dominate the Neuroendocrine Tumor Treatment Market

North America is found dominating the neuroendocrine tumors market, due to the rising incidence of neuroendocrine diseases, developed health care infrastructure, strong clinical pipeline, high level of awareness among people and presence of key market players. There are also supportive insurance policies in this region facilitating neuroendocrine treatment, such as Medicare, Medicaid, and Tricare that helps in driving the overall growth of the market.

Asia Pacific market is also anticipated to witness significant growth due to the rising incidence of neuroendocrine tumors in the region.

Neuroendocrine Tumor Treatment Market Growth

Competitive Landscape

The key players are found undertaking strategies such as product launches, regional expansion, partnership and distribution agreements, to strengthen their market position. There are also various companies that are found focusing on organic growth strategies product approvals and others such as patents and events. The inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Neuroendocrine Carcinoma

      2. 4.2.2 Technological Advancements

      3. 4.2.3 Rising Number of Government Initiatives

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Development

      2. 4.3.2 Lack of Awareness Among People

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Products

      1. 5.1.1 Somatostatin Analogs (SSAs)

      2. 5.1.2 Targeted Therapy

      3. 5.1.3 Chemotherapy

      4. 5.1.4 Others

    2. 5.2 By Indication

      1. 5.2.1 Lungs

      2. 5.2.2 Pancreas

      3. 5.2.3 Gastrointestinal

      4. 5.2.4 Others

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Clinics

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Boehringer Ingelheim International GmbH

      2. 6.1.2 Bristol-Myers Squibb

      3. 6.1.3 Eli Lilly & Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd.

      5. 6.1.5 Ipsen

      6. 6.1.6 Novartis AG

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Progenics Pharmaceuticals

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Neuroendocrine Tumor Treatment Market market is studied from 2018 - 2026.

The Neuroendocrine Tumor Treatment Market is growing at a CAGR of 10% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer Inc., Novartis AG, Ipsen, Boehringer Ingelheim International GmbH, Eli Lilly & Company are the major companies operating in Neuroendocrine Tumor Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!